Summary: In this phase 1, single-ascending-dose first-in-human trial in healthy and obese Chinese adults, single doses of HEC88473 (0.5 to 62.9 mg), a long-acting dual GLP-1 and FGF21 receptor agonist, were well tolerated, with mostly mild gastrointestinal events. Early pharmacodynamic signals were seen, including a placebo-adjusted glucose reduction of 1.829 mmol/L in the 47.6 mg group, adiponectin increases up to 90.71%, and triglyceride reductions up to 43.01% in the 62.9 mg group. These are early-phase biomarker signals, not proven clinical efficacy.
PICO Summary
| Element | Detail |
|---|---|
| Population | Healthy and obese Chinese adults; phase 1, randomised, placebo-controlled, single-ascending-dose first-in-human trial (NCT05943886). |
| Intervention | Single subcutaneous doses of HEC88473 (0.5 to 62.9 mg), a long-acting Fc-fusion dual GLP-1 and FGF21 receptor agonist. |
| Comparison | Placebo, within the dose-escalation cohorts. |
| Outcome | Well tolerated; most treatment-related adverse events were mild gastrointestinal disorders. Pharmacodynamic signals (no efficacy hypothesis testing reported): largest OGTT serum glucose reduction of -1.829 mmol/L in the 47.6 mg group (baseline and placebo adjusted); adiponectin increase up to +90.71% and triglyceride reduction up to -43.01% in the 62.9 mg group; effects were dose- and time-related. Half-lives: HEC88473 16.2 to 22.6 h, Fc-GLP-1 66.5 to 119.5 h, Fc-FGF21 28.4 to 41.6 h. No 95% CIs, p values, ARR, or NNT are applicable to this early-phase design. |
Expert Commentary
The verdict is that this is a clean, encouraging first-in-human safety and pharmacodynamic readout, and nothing more. As a single-ascending-dose phase 1 study, it was designed to characterise tolerability and pharmacokinetics, not to prove that HEC88473 lowers glucose, weight, or cardiometabolic risk over time. The reported glucose, adiponectin, and triglyceride changes are exploratory biomarker movements in small dose cohorts, with no confirmatory efficacy hypothesis testing, so they should be read as biological plausibility signals rather than treatment effects. The principal limitation is dose-range immaturity: the largest metabolic signals cluster at the highest single doses, where the durability, the dose-response shape on repeated dosing, and the gastrointestinal tolerability ceiling all remain undefined. Two further cautions are warranted. The study population was healthy and obese volunteers rather than people with established type 2 diabetes, and several authors are affiliated with the manufacturer, so independent replication matters. Can I use this with my patients? Not yet. There is no patient for whom this agent is currently appropriate outside a trial, and clinicians should not extrapolate the biomarker numbers to expected clinical benefit. The reasonable wish is for adequately powered, longer multiple-ascending-dose and phase 2 studies in people with type 2 diabetes or metabolic disease, with hard glycaemic and weight endpoints, before any clinical optimism is justified.
References
Zhang H, Li Q, Chen H, Guo L, Li J, Xie C, Yan J, Ding Y. First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects. BioDrugs. 2025;39(3):477-486. doi:10.1007/s40259-025-00715-3
